ALK-Abelló A/S

CPSE:ALK B Stok Raporu

Piyasa değeri: DKK 56.6b

ALK-Abelló Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

ALK-Abelló 0.64% cari getiri oranına sahip temettü ödeyen bir şirkettir.

Anahtar bilgiler

0.6%

Temettü verimi

-0.002%

Geri Alım Getirisi

Toplam Hissedar Getirisi0.6%
Gelecekteki Temettü Verimi0.5%
Temettü Büyümesi28.9%
Bir sonraki temettü ödeme tarihin/a
Eski temettü tarihin/a
Hisse başına temettün/a
Ödeme oranı28%

Son temettü ve geri alım güncellemeleri

Recent updates

Anlatı Güncellemesi • Jun 12

ALK B: Future Returns Will Reflect Allergy Immunotherapy And Anaphylaxis Treatment Progress

Narrative Update on ALK-Abelló The analyst price target for ALK-Abelló has been updated to DKK 305, with analysts pointing to the company’s position as a global market leader in allergy immunotherapy as a key factor in this valuation. What's in the News At the 2026 EAACI Congress, ALK presented data on real world anaphylaxis management, highlighting frequent gaps in adrenaline auto injector use.
Anlatı Güncellemesi • May 29

ALK B: Future Upside Will Come From Allergy Immunotherapy Leadership

Analysts have lifted their price target on ALK-Abelló from DKK 263.33 to DKK 297.50, citing the company’s position as a global leader in allergy immunotherapy and recent supportive research coverage. Analyst Commentary Analysts setting a DKK 305 price target frame ALK-Abelló as a global leader in allergy immunotherapy, and they use that positioning to support a constructive view on the stock’s long term potential.
Anlatı Güncellemesi • Apr 24

ALK B: Future Upside Will Come From Needle Free Anaphylaxis Treatment Adoption

Analysts have nudged their price target for ALK-Abelló to DKK 263.33 from DKK 255, reflecting updated assumptions around slightly adjusted revenue growth, profit margin expectations, and a higher future P/E multiple. What's in the News ALK reported positive topline phase 2 data from the ALLIANCE trial of its once daily sublingual immunotherapy tablet for peanut allergy in patients aged 4 to 65 years, with statistically significant, dose dependent efficacy across multiple tolerated dose and eliciting dose endpoints and a safety profile without treatment related anaphylaxis or serious adverse events (Key Developments).
Anlatı Güncellemesi • Apr 09

ALK B: Future Upside Will Come From Wider Needle Free Anaphylaxis Treatment Adoption

Analysts have adjusted their DKK price targets for ALK-Abelló to reflect updated assumptions for revenue growth of 13.31%, profit margin of 20.66% and a future P/E of 34.79. This suggests a modest recalibration in how the company’s earnings power is being valued.
Anlatı Güncellemesi • Mar 25

ALK B: Future Upside Will Rely On Wider Anaphylaxis Spray Adoption

Analysts have kept their DKK price target for ALK-Abelló broadly unchanged at DKK 255, reflecting stable assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. This signals a steady view on the company’s outlook.
Anlatı Güncellemesi • Mar 11

ALK B: Future Upside Will Rely On Wider Anaphylaxis Treatment Adoption

Analysts have kept their DKK 255.00 price target for ALK-Abelló unchanged, indicating that their views on fair value, discount rate, expected revenue growth, profit margin and future P/E assumptions remain broadly steady. What's in the News ALK-Abelló presented late-breaking data from a 90-participant study comparing needle-free EURneffy nasal adrenaline to injectable auto-injectors for anaphylaxis, with 88% of participants preferring EURneffy, mainly for ease of use, portability and the absence of a needle (AAAAI 2026 Annual Meeting).
Anlatı Güncellemesi • Feb 25

ALK B: Future Returns Will Rely On Expanded Anaphylaxis Indications And Stronger Margins

Analysts have nudged their price target on ALK-Abelló up from DKK 249 to DKK 255, reflecting updated assumptions that combine slightly lower expected revenue growth with a higher projected profit margin and a modestly lower future P/E multiple. What's in the News ALK Abelló issued earnings guidance for 2026, indicating an expectation of continued double digit revenue growth and higher earnings, with revenue projected to grow 11 to 15% in local currencies (company guidance).
Anlatı Güncellemesi • Feb 10

ALK B: Future Returns Will Rely On Expanded Anaphylaxis Reach And Higher 2025 Margins

Analysts have lifted their fair value estimate for ALK-Abelló from DKK 214 to DKK 249, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending EU marketing authorisation for EURneffy 1 mg nasal adrenaline spray for emergency treatment of anaphylaxis in children aged 4 years and older weighing 15 kg to 30 kg.
Anlatı Güncellemesi • Jan 27

ALK B: Future Returns Will Reflect Upgraded 2025 Outlook And Stable Margin Ambitions

Analysts have kept their price target for ALK-Abelló steady at DKK 214. This reflects unchanged assumptions around discount rate, revenue growth, profit margin and future P/E, and indicates that new research has not materially shifted their valuation view.
Yeni Anlatı • Jan 23

Pediatric Allergy Tablets And Food Programs Will Drive A Long Runway Of Opportunity

Catalysts About ALK-Abelló ALK Abelló develops and commercialises allergy immunotherapy tablets, injectable and drop therapies, along with anaphylaxis treatments such as Jext and neffy. What are the underlying business or industry changes driving this perspective?
Analiz Makalesi • Jan 23

ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Anlatı Güncellemesi • Jan 12

ALK B: Future Returns Will Reflect Upgraded Outlook And Balanced Margin Prospects

Analysts have trimmed their price target for ALK-Abelló to €214.00 from €219.33, citing updated assumptions that now reflect slightly higher revenue growth, a modestly lower profit margin outlook and a small adjustment to the projected future P/E multiple. What's in the News ALK-Abelló upgraded its earnings guidance for the full year 2025, with expected revenue growth of 13% to 15% in local currencies, compared with a previous range of 12% to 14% (Key Developments).
Anlatı Güncellemesi • Dec 19

ALK B: Future Returns Will Reflect Upgraded Outlook And Solid Margin Prospects

Analysts have modestly lifted their average price target on ALK-Abelló to DKK 219.33, reflecting steady confidence in the company’s unchanged long term growth, margin, and valuation assumptions despite minimal adjustments to underlying model inputs. What's in the News Upgraded 2025 revenue guidance to 13% to 15% growth in local currencies, from 12% to 14%, supported by stronger demand across all regions and product lines (company guidance).
Analiz Makalesi • Dec 08

Investors Appear Satisfied With ALK-Abelló A/S' (CPH:ALK B) Prospects

With a price-to-earnings (or "P/E") ratio of 45.8x ALK-Abelló A/S ( CPH:ALK B ) may be sending very bearish signals at...
Anlatı Güncellemesi • Dec 05

ALK B: Future Returns Will Reflect China Alliance And Margin Outlook

Analysts have maintained their DKK 219.33 price target for ALK Abelló, reflecting stable expectations for sustained double digit revenue growth, robust profit margins and a premium future P E multiple. What's in the News Upgraded 2025 guidance, with expected revenue growth raised to 13% to 15% in local currencies, supported by higher treatment volumes across allergy immunotherapy and anaphylaxis products, and an improved projected EBIT margin of about 26% (company guidance).
Anlatı Güncellemesi • Nov 21

ALK B: Improved Margins and China Partnership Will Drive Steady Outlook

Analysts have raised their price target for ALK-Abelló to DKK 219.33 from DKK 196.00. They cite ongoing improvements in profit margins and a slightly higher projected fair value as the reasons for the adjustment.
Analiz Makalesi • Nov 15

ALK-Abelló A/S (CPH:ALK B) Just Reported And Analysts Have Been Lifting Their Price Targets

It's been a pretty great week for ALK-Abelló A/S ( CPH:ALK B ) shareholders, with its shares surging 15% to kr.230 in...
Anlatı Güncellemesi • Nov 04

ALK B: Chinese Partnership And Revenue Upside Will Drive Future Opportunities

Analysts have raised their price target for ALK-Abelló from DKK 193 to DKK 196. This change is based on slightly improved revenue growth estimates and valuation adjustments.
Analiz Makalesi • Oct 11

Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Anlatı Güncellemesi • Aug 23

Allergy+ Strategy Will Reach Millions With New Therapies

The increase in ALK-Abelló’s analyst price target is primarily driven by a modest upward revision in consensus revenue growth forecasts, while net profit margins remain steady, resulting in a new fair value estimate of DKK192.33 per share. What's in the News ALK-Abelló raised its 2025 revenue growth guidance to 12-14% (from 9-13%) in local currencies, supported by strong adrenaline autoinjector and tablet sales in Europe and North America, and will allocate additional funds to strategic growth investments.
Analiz Makalesi • Jul 23

ALK-Abelló A/S' (CPH:ALK B) Popularity With Investors Is Clear

With a price-to-earnings (or "P/E") ratio of 44.9x ALK-Abelló A/S ( CPH:ALK B ) may be sending very bearish signals at...
User avatar
Yeni Anlatı • Dec 11

Allergy+ Strategy And Neffy Nasal Spray Will Ignite Revenue Growth And Boost Earnings

The Allergy+ strategy and neffy nasal spray deal are expected to create new revenue streams and drive growth from 2025 onward.

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ALK B Danish piyasası için dikkate değer bir temettü ödemesi yapmıyor, bu nedenle ödemelerin istikrarlı olup olmadığını kontrol etmeye gerek yok.

Büyüyen Temettü: ALK B Danish piyasası için dikkate değer bir temettü ödemiyor, bu nedenle ödemelerin artıp artmadığını kontrol etmeye gerek yok.

Piyasaya Karşı Temettü Getirisi

ALK-Abelló Piyasaya Karşı Temettü Getirisi
ALK B temettü verimi piyasa ile karşılaştırıldığında nasıldır?
SegmentTemettü Verimi
Şirket (ALK B)0.6%
Pazarın Alt %25'i (DK)1.5%
Pazarın En İyi %25'i (DK)4.4%
Sektör Ortalaması (Pharmaceuticals)2.8%
Analist tahmini (ALK B) (3 yıla kadar)0.5%

Önemli Temettü: ALK B şirketinin temettüsü ( 0.64% ), Danish pazarındaki temettü ödeyenlerin en alttaki %25'ine ( 1.55% ) kıyasla dikkate değer değil.

Yüksek Temettü: ALK B 'in temettüsü ( 0.64% ), Danish piyasasındaki temettü ödeyenlerin en üst %25'ine ( 4.35% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: ALK B Danish piyasası için dikkate değer bir temettü ödemiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: ALK B Danish piyasası için dikkate değer bir temettü ödemiyor.

Güçlü temettü ödeyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/06/19 22:49
Gün Sonu Hisse Fiyatı2026/06/19 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

ALK-Abelló A/S 9 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
null nullABG Sundal Collier
Mads Brinkmann AndersenBerenberg
Jesper IlsoeCarnegie Investment Bank AB